• Je něco špatně v tomto záznamu ?

Outcomes of stereotactic radiosurgery for pituitary metastases: an international multi-institutional study

H. Abou-Al-Shaar, I. Albalkhi, RK. Shariff, AN. Mallela, PK. Fazeli, SM. Tos, G. Mantziaris, Y. Meng, K. Bernstein, T. Kaisman-Elbaz, H. Abofani, YY. Lin, CC. Lee, M. Tripathi, R. Upadhyay, JD. Palmer, AM. Nabeel, WA. Reda, SR. Tawadros, K....

. 2025 ; 28 (3) : 69. [pub] 20250529

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015625

BACKGROUND: Pituitary metastases (PM) account for 0.4% of all intracranial metastases and typically present with visual and endocrinological deficits. Stereotactic radiosurgery (SRS) has shown excellent tumor control and safety profile in the management of intracranial metastases. However, its role and safety in managing metastases to the pituitary gland are not well-characterized. This study aims to evaluate SRS outcomes and safety profile in the management of PM in a multicenter international cohort. METHODS: The authors retrospectively analyzed data from 63 patients with PM treated with SRS across 12 institutions, assessing clinical and radiological outcomes, including survival rates, tumor control, visual and endocrinological outcomes, and post-treatment complications. RESULTS: Among 63 patients included in the study (median tumor volume: 1.5 cc), SRS demonstrated a local tumor control rate of 93.1% at 12 months. The median survival was 25.4 months and overall survival rates of 77.6%, 65.9%, and 55.1% at 6, 12, and 18 months, respectively. In multivariate analysis, a margin dose for PM > 10 Gy emerged as an independent predictor across progression-free survival (HR: 0.20, p < 0.01), distant metastasis-free survival (HR: 0.30, p = 0.01), and overall survival. (HR: 0.15, p < 0.01). Following SRS, most patients showed stable or improved visual function (n = 17/18). A small percentage of patients experienced complications: developed new visual deficits (n = 1/63), experienced new anterior pituitary hormone deficiency (n = 5/63), and developed arginine vasopressin (AVP)-deficiency post-treatment (n = 2/63). CONCLUSION: SRS is an important modality in the management of PM, offering excellent local tumor control and survival outcomes with minimal morbidity. These findings support the incorporation of SRS into the multidisciplinary management for treating patients with PM.

Clinical Oncology Department Ain shams University Cairo Egypt

Department of Neurological Surgery University of Pittsburgh Medical Center Pittsburgh PA USA

Department of Neurological Surgery University of Virginia Charlottesville VA USA

Department of Neurosurgery Allegheny Health Network Cancer Institute Pittsburgh PA USA

Department of Neurosurgery Koc University School of Medicine Istanbul Turkey

Department of Neurosurgery Neurological Institute Taipei Veterans General Hospital Taipei Taiwan

Department of Neurosurgery NYU Langone Medical Center New York University New York USA

Department of Neurosurgery PGIMER Chandigarh India

Department of Neurosurgery Sheba Medical Center Ramat Gan Israel

Department of Neurosurgery University of Miami Health System Miami FL USA

Department of Radiation Oncology Allegheny Health Network Cancer Institute Pittsburgh PA USA

Department of Radiation Oncology NYU Langone Medical Center New York University New York USA

Department of Stereotactic and Radiation Neurosurgery Na Homolce Hospital Prague Czechia Czechia

Division of Endocrinology Department of Medicine University of Pittsburgh Medical Center Pittsburgh PA USA

Gamma Knife Centre Nasser Institute Cairo Egypt

Neurosurgery Department Benha University Qualyobia Egypt

Radiation Oncology Department National Cancer Institute Cairo University Cairo Egypt

Radiation Oncology The James Cancer Center Ohio State University Columbus OH USA

Stereotactic and Functional Neurosurgery University of British Columbia Vancouver Canada

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015625
003      
CZ-PrNML
005      
20250731091130.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11102-025-01542-z $2 doi
035    __
$a (PubMed)40442537
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Abou-Al-Shaar, Hussam $u Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. aboualshaarh@upmc.edu
245    10
$a Outcomes of stereotactic radiosurgery for pituitary metastases: an international multi-institutional study / $c H. Abou-Al-Shaar, I. Albalkhi, RK. Shariff, AN. Mallela, PK. Fazeli, SM. Tos, G. Mantziaris, Y. Meng, K. Bernstein, T. Kaisman-Elbaz, H. Abofani, YY. Lin, CC. Lee, M. Tripathi, R. Upadhyay, JD. Palmer, AM. Nabeel, WA. Reda, SR. Tawadros, K. Abdelkarim, AMN. El-Shehaby, RM. Emad, S. Peker, Y. Samanci, RE. Wegner, MJ. Shepard, R. Liscak, G. Simonova, T. Almeida, C. Benjamin, D. Kondziolka, JP. Sheehan, A. Niranjan, CG. Hadjipanayis, LD. Lunsford
520    9_
$a BACKGROUND: Pituitary metastases (PM) account for 0.4% of all intracranial metastases and typically present with visual and endocrinological deficits. Stereotactic radiosurgery (SRS) has shown excellent tumor control and safety profile in the management of intracranial metastases. However, its role and safety in managing metastases to the pituitary gland are not well-characterized. This study aims to evaluate SRS outcomes and safety profile in the management of PM in a multicenter international cohort. METHODS: The authors retrospectively analyzed data from 63 patients with PM treated with SRS across 12 institutions, assessing clinical and radiological outcomes, including survival rates, tumor control, visual and endocrinological outcomes, and post-treatment complications. RESULTS: Among 63 patients included in the study (median tumor volume: 1.5 cc), SRS demonstrated a local tumor control rate of 93.1% at 12 months. The median survival was 25.4 months and overall survival rates of 77.6%, 65.9%, and 55.1% at 6, 12, and 18 months, respectively. In multivariate analysis, a margin dose for PM > 10 Gy emerged as an independent predictor across progression-free survival (HR: 0.20, p < 0.01), distant metastasis-free survival (HR: 0.30, p = 0.01), and overall survival. (HR: 0.15, p < 0.01). Following SRS, most patients showed stable or improved visual function (n = 17/18). A small percentage of patients experienced complications: developed new visual deficits (n = 1/63), experienced new anterior pituitary hormone deficiency (n = 5/63), and developed arginine vasopressin (AVP)-deficiency post-treatment (n = 2/63). CONCLUSION: SRS is an important modality in the management of PM, offering excellent local tumor control and survival outcomes with minimal morbidity. These findings support the incorporation of SRS into the multidisciplinary management for treating patients with PM.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádory hypofýzy $x mortalita $x radioterapie $x sekundární $7 D010911
650    12
$a radiochirurgie $x škodlivé účinky $x metody $x statistika a číselné údaje $7 D016634
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Albalkhi, Ibrahem $u Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
700    1_
$a Shariff, Rimsha K $u Division of Endocrinology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
700    1_
$a Mallela, Arka N $u Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
700    1_
$a Fazeli, Pouneh K $u Division of Endocrinology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
700    1_
$a Tos, Salem M $u Department of Neurological Surgery, University of Virginia, Charlottesville, VA, USA
700    1_
$a Mantziaris, Georgios $u Department of Neurological Surgery, University of Virginia, Charlottesville, VA, USA
700    1_
$a Meng, Ying $u Department of Neurosurgery, NYU Langone Medical Center, New York University, New York, USA
700    1_
$a Bernstein, Kenneth $u Department of Radiation Oncology, NYU Langone Medical Center, New York University, New York, USA
700    1_
$a Kaisman-Elbaz, Tehila $u Department of Neurosurgery, Sheba Medical Center, Ramat Gan, Israel
700    1_
$a Abofani, Hanan $u Department of Neurosurgery, Sheba Medical Center, Ramat Gan, Israel
700    1_
$a Lin, Yen-Yu $u Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
700    1_
$a Lee, Cheng-Chia $u Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
700    1_
$a Tripathi, Manjul $u Department of Neurosurgery, PGIMER, Chandigarh, India
700    1_
$a Upadhyay, Rituraj $u Radiation Oncology, The James Cancer Center, Ohio State University, Columbus, OH, USA
700    1_
$a Palmer, Joshua D $u Radiation Oncology, The James Cancer Center, Ohio State University, Columbus, OH, USA
700    1_
$a Nabeel, Ahmed M $u Gamma Knife Centre - Nasser Institute, Cairo, Egypt $u Neurosurgery Department, Benha University, Qualyobia, Egypt
700    1_
$a Reda, Wael A $u Gamma Knife Centre - Nasser Institute, Cairo, Egypt $u Neurosurgery Department, Benha University, Qualyobia, Egypt
700    1_
$a Tawadros, Sameh R $u Gamma Knife Centre - Nasser Institute, Cairo, Egypt $u Neurosurgery Department, Benha University, Qualyobia, Egypt
700    1_
$a Abdelkarim, Khaled $u Gamma Knife Centre - Nasser Institute, Cairo, Egypt $u Clinical Oncology Department - Ain shams University, Cairo, Egypt
700    1_
$a El-Shehaby, Amr M N $u Gamma Knife Centre - Nasser Institute, Cairo, Egypt $u Neurosurgery Department, Benha University, Qualyobia, Egypt
700    1_
$a Emad, Reem M $u Gamma Knife Centre - Nasser Institute, Cairo, Egypt $u Radiation Oncology Department - National Cancer Institute, Cairo University, Cairo, Egypt
700    1_
$a Peker, Selcuk $u Department of Neurosurgery, Koc University School of Medicine, Istanbul, Turkey
700    1_
$a Samanci, Yavuz $u Department of Neurosurgery, Koc University School of Medicine, Istanbul, Turkey
700    1_
$a Wegner, Rodney E $u Department of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA
700    1_
$a Shepard, Matthew J $u Department of Neurosurgery, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA
700    1_
$a Liscak, Roman $u Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czechia, Czechia
700    1_
$a Simonova, Gabriela $u Stereotactic and Functional Neurosurgery, University of British Columbia, Vancouver, Canada
700    1_
$a Almeida, Timoteo $u Stereotactic and Functional Neurosurgery, University of British Columbia, Vancouver, Canada
700    1_
$a Benjamin, Carolina $u Department of Neurosurgery, University of Miami Health System, Miami, FL, USA
700    1_
$a Kondziolka, Douglas $u Department of Neurosurgery, NYU Langone Medical Center, New York University, New York, USA
700    1_
$a Sheehan, Jason P $u Department of Neurological Surgery, University of Virginia, Charlottesville, VA, USA
700    1_
$a Niranjan, Ajay $u Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
700    1_
$a Hadjipanayis, Constantinos G $u Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
700    1_
$a Lunsford, L Dade $u Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
773    0_
$w MED00007807 $t Pituitary $x 1573-7403 $g Roč. 28, č. 3 (2025), s. 69
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40442537 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091125 $b ABA008
999    __
$a ok $b bmc $g 2366467 $s 1252750
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 28 $c 3 $d 69 $e 20250529 $i 1573-7403 $m Pituitary $n Pituitary $x MED00007807
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace